VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
Rifaximin /day
Preclinical
Small molecule
P
Pomeranian Medical University Szczecin
1
Indications
1
Total Trials
0
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Probiotics
Completed
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Probiotics
Preclinical
Completed
Clinical
Trials by Indication
[1]
Probiotics
1 trial
The Efficacy of Probiotics as an Adjunct to Treatment of SIBO With Rifaximin
Completed
·
P
Pomeranian Medical University Szczecin
·
N/A
·
NCT06223685
·
129 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
1 trial record for Rifaximin /day. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
Rifaximin /day compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for Rifaximin /day. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Pomeranian Medical University Szczecin company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Preclinical
[1]
Company
P
Pomeranian Medical University Szczecin
Related News